Celexa/Lexapro MDL winds up
Celexa/Lexapro MDL winds up
Introduction
The U.S. District Judge Nathaniel M. Gorton granted Forest Laboratories’ motion for summary judgment on all claims made by the plaintiffs who alleged that the company fraudulently promoted Celexa and Lexapro for pediatric depression. This ruling brings an end to the long-running Massachusetts MDL 2067: In Re: Celexa and Lexapro Marketing and Sales Practices Litigation.
Comments
Latest News
New Front Emerges in Fight Against Synthetic Opioids
Categories: Opioids
The U.S. opioid crisis has already claimed hundreds of thousands of lives, with fentanyl standing out as one of the deadliest substances. Now the leading cause of death among Americans aged 18 to 44, fentanyl has become synonymous with overdose…
Exactech to Pay $8M to Settle Defective Knee Implant Suit
Categories: Attune Knee System
Medical device maker Exactech has agreed to an $8 million settlement to resolve allegations that it hid defects in a widely used line of artificial knee implants.
The implants have been linked to thousands of patient injuries and sparked…
Talcum Powder Cancer Settlement Talks Begin Sept. 4
Categories: Talcum
Representatives of Johnson & Johnson (J&J) and attorneys for tens of thousands of plaintiffs involved in talcum powder lawsuits are scheduled to meet in September 2025 in an…